CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Citing CVS spokesperson David Whitrap, Bloomberg News reported that “Zepbound will be excluded” in health plans using ... in those plans could switch to Wegovy, while exceptions will be ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

Starting July 1, CVS said Wegovy will be the preferred weight-loss ... while membership increased by 1.1%. For health services, which include CVS Caremark, revenue increased 7.9% to $43.46 billion ...

Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...